ABIM Laboratory Test Reference Ranges ̶ July 2023
Laboratory Tests
1,25-Dihydroxyvitamin D
(1,25-dihydroxycholecalciferol), serum
17-Hydroxyprogesterone, serum
Female, follicular
Female, luteal
Female, postmenopausal
Male (adult)
25-Hydroxyvitamin D
(25-hydroxycholecalciferol), serum
5-Hydroxyindoleacetic acid, urine
6-Thioguanine, whole blood
Absolute neutrophil count (ANC)
Reference Ranges
See Vitamin D metabolites
˂80 ng/dL
˂285 ng/dL
˂51 ng/dL
˂220 ng/dL
See Vitamin D metabolites
2–9 mg/24 hr
230–400 pmol/8x108 RBCs
2000–8250/μL
Acid phosphatase, serum
Total
Prostatic fraction
ACTH, plasma
Activated partial thromboplastin time
0.5–2.0 (Bodansky) units/mL
0.1–0.4 unit/mL
10–60 pg/mL
25–35 seconds
ADAMTS13 activity
Adrenocorticotropic hormone (ACTH), plasma
Albumin, serum
Albumin, urine
Albumin-to-creatinine ratio, urine
Aldolase, serum
>60%
10–60 pg/mL
3.5–5.5 g/dL
˂25 mg/24 hr
˂30 mg/g
0.8–3.0 IU/mL
Aldosterone, plasma
Supine or seated
Standing
Low-sodium diet (supine)
Aldosterone, urine
Alkaline phosphatase, serum
≤10 ng/dL
˂21 ng/dL
≤30 ng/dL
5–19 μg/24 hr
30–120 U/L
Alpha1-antitrypsin (AAT), serum
150–350 mg/dL
Alpha2-antiplasmin activity, plasma
Alpha-amino nitrogen, urine
Alpha-fetoprotein, serum
Amino acids, urine
Aminotransferase, serum alanine (ALT, SGPT)
Aminotransferase, serum aspartate (AST, SGOT)
Ammonia, plasma
Amylase, serum
Amylase, urine
Androstenedione, serum
Angiotensin-converting enzyme, serum
Anion gap, serum
Antibodies to double-stranded DNA
75%–115%
100–290 mg/24 hr
˂10 ng/mL
200–400 mg/24 hr
10–40 U/L
10–40 U/L
40–70 μg/dL
25–125 U/L (80–180 [Somogyi] units/dL)
1–17 U/hr
Female: 30–200 ng/dL; male: 40–150 ng/dL
8–53 U/L
7–13 mEq/L
0–7 IU/mL
Anticardiolipin antibodies
IgG
IgM
˂20 GPL
˂20 MPL
Anti-cyclic citrullinated peptide, antibodies to
Antideoxyribonuclease B
˂20 units
˂280 units
Anti-F-actin antibodies, serum
Antihistone antibodies
Anti-liver-kidney microsomal antibodies (anti-LKM)
Antimitochondrial antibodies
≤1:80
˂1:16
˂1:20
≤1:5
Anti–myelin associated glycoprotein antibody
Antimyeloperoxidase antibodies
Antinuclear antibodies
Anti–smooth muscle antibodies
Antistreptolysin O titer
Antithrombin activity
Antithyroglobulin antibodies
Antithyroid peroxidase antibodies
Anti-tissue transglutaminase antibodies
˂1:1600
˂1.0 U
≤1:40
≤1:80
˂200 Todd units
80%–120%
˂20 U/mL
˂2.0 U/mL
See Tissue transglutaminase antibody
Arterial blood gas studies (patient
breathing room air):
pH
PaCO2
PaO2
Bicarbonate
Oxygen saturation
Methemoglobin
7.38–7.44
38–42 mm Hg
75–100 mm Hg
23–26 mEq/L
≥95%
0.5%–3.0%
Ascorbic acid (vitamin C), blood
Ascorbic acid, leukocyte
0.4–1.5 mg/dL
16.5 ± 5.1 mg/dL of leukocytes
(1,3)-Beta-D-glucan, serum Beta-human chorionic gonadotropin (beta-hCG), serum
˂60 pg/mL
Female, premenopausal nonpregnant: ˂1.0 U/L;
female, postmenopausal: ˂7.0 U/L; male: ˂1.4 U/
L˂2 mIU/24 hr
Beta-human chorionic gonadotropin (beta-hCG), urine
Beta2-glycoprotein I antibodies:
IgG
IgM
Beta-hydroxybutyrate, serum
Beta2-microglobulin, serum
Bicarbonate, serum
˂21 SGU
˂21 SMU
˂0.4 mmol/L
0.54–2.75 mg/L
23–28 mEq/L
Bilirubin, serum
Total
Direct
Indirect
0.3–1.0 mg/dL
0.1–0.3 mg/dL
Bleeding time (template)
Blood urea nitrogen (BUN), serum or plasma
Bone-specific alkaline phosphatase, serum
B-type natriuretic peptide, plasma
C peptide, serum
0.2–0.7 mg/dL
˂8 minutes
8–20 mg/dL
Female, premenopausal: 4.5–16.9 µg/L
Female, postmenopausal: 7.0–22.4 µg/L
Male, 25 years of age or older: 6.5–20.1 µg/L
˂100 pg/mL
0.8–3.1 ng/mL
2
Calcitonin, serum
Calcium, ionized, serum
Calcium, serum
Female: ≤5 pg/mL; male: ≤10 pg/mL
1.12–1.23 mmol/L
8.6–10.2 mg/dL
Calcium, urine
Female: ˂250 mg/24 hr; male: ˂300 mg/24 hr
Carbohydrate antigens, serum
CA 19-9
CA 27-29
CA 125
0–37 U/mL
˂38.0 U/mL
˂35 U/mL
Carbon dioxide content, serum
Carboxyhemoglobin, blood
Carcinoembryonic antigen, plasma
Carotene, serum
23–30 mEq/L
˂5%
˂2.5 ng/mL
75–300 μg/dL
Catecholamines, plasma
Dopamine
Epinephrine
Supine
Standing
Norepinephrine
Supine
Standing
˂30 pg/mL
˂50 pg/mL
˂95 pg/mL
112–658 pg/mL
217–1109 pg/mL
Catecholamines, urine
Dopamine
Epinephrine
Norepinephrine
Total
65–400 μg/24 hr
2–24 μg/24 hr
15–100 μg/24 hr
26–121 μg/24 hr
CD4 T-lymphocyte count
530–1570/μL
Cell count, CSF:
Leukocytes (WBCs)
Erythrocytes (RBCs)
0–5 cells/μL
0/µL
Ceruloplasmin, serum (plasma)
Chloride, CSF
Chloride, serum
25–43 mg/dL
120–130 mEq/L
98–106 mEq/L
Chloride, urine
Random ("spot")
24-hour measurement
mEq/L; varies
mEq/24 hr; varies with intake
Cholesterol, serum
Total
Desirable
Borderline-high
High
High-density lipoprotein
Low
Low-density lipoprotein
Optimal
Near-optimal
Borderline-high
High
Very high
˂200 mg/dL
200–239 mg/dL
>239 mg/dL
Female: ˂50 mg/dL; male: ˂40 mg/dL
˂100 mg/dL
100–129 mg/dL
130–159 mg/dL
160–189 mg/dL
>189 mg/dL
3
Cholinesterase, serum (pseudocholinesterase)
Packed cells
Chorionic gonadotropin, beta-human
(beta-hCG), serum
Chorionic gonadotropin, beta-human
(beta-hCG), urine
Chromogranin A, serum
Citrate, urine
Coagulation factors, plasma
Factor I (fibrinogen)
Factor II (prothrombin)
Factor V (accelerator globulin)
Factor VII (proconvertin)
Factor VIII (antihemophilic globulin)
Factor IX (plasma thromboplastin component)
Factor X (Stuart factor)
Factor XI (plasma thromboplastin antecedent)
Factor XII (Hageman factor)
Factor XIII
≥0.5 pH unit/hr
≥0.7 pH unit/hr
See Beta-human chorionic gonadotropin (beta-hCG),
serum
See Beta-human chorionic gonadotropin (beta-hCG),
urine
˂93 ng/mL
250–1000 mg/24 hr
Cold agglutinin titer
Complement components, serum
C3
C4
CH50
>1:64 positive
Copper, serum
Copper, urine
Coproporphyrin, urine
Cortisol, free, urine
100–200 μg/dL
0–100 μg/24 hr
50–250 μg/24 hr
4–50 μg/24 hr
Cortisol, plasma
8 AM
4 PM
1 hour after cosyntropin
Overnight suppression test (1-mg)
Overnight suppression test (8-mg)
5–25 μg/dL
˂10 μg/dL
≥18 μg/dL
˂1.8 μg/dL
>50% reduction in cortisol
Cortisol, saliva, 11 PM – midnight
C-reactive protein, serum
C-reactive protein (high sensitivity), serum
Creatine kinase, serum
Total
MB isoenzymes
Creatine, urine
Creatinine clearance, urine
Creatinine, serum
200–400 mg/dL
60%–130%
60%–130%
60%–130%
50%–150%
60%–130%
60%–130%
60%–130%
60%–130%
57%–192%
100–233 mg/dL
14–48 mg/dL
110–190 units/mL
˂0.09 µg/dL
≤0.8 mg/dL
Low risk: ˂1.0 mg/L; Average risk: 1.0–3.0 mg/L;
High risk: >3.0 mg/L
Female: 30–135 U/L; male: 55–170 U/L
˂5% of total
Female: 0–100 mg/24 hr; male: 0–40 mg/24 hr
2
90–140 mL/min/1.73 m
Female: 0.50–1.10 mg/dL; male: 0.70–1.30 mg/dL
Creatinine, urine
Random ("spot")
24-hour measurement
mg/dL; varies
15–25 mg/kg body weight/24 hr
Cyclosporine, whole blood (trough)
Therapeutic
0–3 months post transplantation
More than 3 months post transplantation
100–200 ng/mL
150–250 ng/mL
75–125 ng/mL
4
D-dimer, plasma
Dehydroepiandrosterone sulfate (DHEA-S), serum
˂0.5 μg/mL
Female: 44–332 μg/dL; male: 89–457 μg/dL
Delta-aminolevulinic acid, serum
Digoxin, serum
Dihydrotestosterone, serum
Dopamine, plasma
Dopamine, urine
˂20 μg/dL
Therapeutic: 1.0–2.0 ng/mL
(˂1.2 ng/mL for patients with heart failure)
Adult male: 25–80 ng/dL
˂30 pg/mL
65–400 μg/24 hr
D-Xylose absorption
(after ingestion of 25 g of D-xylose)
Serum
Urinary excretion
25–40 mg/dL
4.5–7.5 g during a 5-hr period
Electrolytes, serum
Sodium
Potassium
Chloride
Bicarbonate
136–145 mEq/L
3.5–5.0 mEq/L
98–106 mEq/L
23–28 mEq/L
Epinephrine, plasma
Supine
Standing
˂110 pg/mL
˂140 pg/mL
Epinephrine, urine
Erythrocyte count
Erythrocyte sedimentation rate (Westergren)
Erythrocyte survival rate (51Cr)
Erythropoietin, serum
˂20 μg/24 hr
4.2–5.9 million/μL
Female: 0–20 mm/hr; male: 0–15 mm/hr
T½ = 28 days
4–26 mU/mL
Estradiol, serum
Female, follicular
Mid-cycle peak
Luteal
Postmenopausal
Male
10–180 pg/mL
100–300 pg/mL
40–200 pg/mL
˂10 pg/mL
20–50 pg/mL
Estriol, urine
Estrogen receptor protein
>12 mg/24 hr
Negative: ˂10 fmol/mg protein
Estrone, serum
Ethanol, blood
Coma level
Intoxication
Euglobulin clot lysis time
Everolimus, whole blood (trough)
10–60 pg/mL
˂0.005% (˂5 mg/dL)
>0.5% (>500 mg/dL)
≥0.08%–0.1% (≥80–100 mg/dL)
Factor XIII, B subunit, plasma
Fecal fat
Fecal nitrogen
Fecal pH
Fecal potassium
Fecal sodium
Fecal urobilinogen
Fecal weight
Ferritin, serum
Fibrin(ogen) degradation products
Fibrinogen, plasma
60–130 U/dL
˂7 g/24 hr
˂2 g/24 hr
7.0–7.5
˂10 mEq/L
˂10 mEq/L
40–280 mg/24 hr
˂250 g/24 hr
Female: 24–307 ng/mL; male: 24–336 ng/mL
˂10 μg/mL
200–400 mg/dL
2–4 hours at 37.0 C
Therapeutic: 3.0–8.0 ng/mL
5
Fibroblast growth factor-23, serum
Flecainide, serum
Folate, red cell
Folate, serum
30–80 RU/mL
Therapeutic: 0.2–1.0 μg/mL
150–450 ng/mL of packed cells
1.8–9.0 ng/mL
Follicle-stimulating hormone, serum
Female, follicular/luteal
Female, mid-cycle peak
Female, postmenopausal
Male (adult)
Children, Tanner stages 1, 2
Children, Tanner stages 3, 4, 5
2–9 mIU/mL (2–9 U/L)
4–22 mIU/mL (4–22 U/L)
>30 mIU/mL (>30 U/L)
1–7 mIU/mL (1–7 U/L)
0.5–8.0 mIU/mL (0.5–8.0 U/L)
1–12 mIU/mL (1–12 U/L)
Free kappa light chain, serum
Free kappa-to-free lambda light chain ratio, serum
Free lambda light chain, serum
Gamma globulin, CSF
Gamma-glutamyltransferase
(gamma-glutamyl transpeptidase), serum
Gastrin, serum
Gentamicin, serum
3.3–19.4 mg/L
0.26–1.65
5.7–26.3 mg/L
6.1–8.3 mg/dL
Female: 8–40 U/L; male: 9–50 U/L
Glucose, CSF
Glucose, plasma (fasting)
Glucose-6-phosphate dehydrogenase, blood
Glycoprotein α-subunit, serum
˂100 pg/mL
Therapeutic: peak 5.0–10.0 µg/mL;
trough: ˂2.0 µg/mL
50–75 mg/dL
70–99 mg/dL
5–15 units/g of hemoglobin
˂1 ng/mL
Growth hormone, serum
At rest
Response to provocative stimuli
˂5 ng/mL
>7 ng/mL
Haptoglobin, serum
Hematocrit, blood
Hemoglobin A1C
Hemoglobin, blood
Hemoglobin fractionation
Hb A
Hb A2
Hb F
83–267 mg/dL
Female: 37%–47%; male: 42%–50%
4.0%–5.6%
Female: 12–16 g/dL; male: 14–18 g/dL
Hemoglobin, plasma
Heparin–anti-factor Xa assay, plasma
˂5.0 mg/dL
0.3–0.7 IU/mL [therapeutic range for standard
(unfractionated) heparin therapy]
Positive: >0.4 optical density unit
25–40 μg/g dry weight
Heparin–platelet factor 4 antibody, serum
Hepatic copper
Hepatic iron index
Histamine excretion, urine
Homocysteine, plasma
β-Human chorionic gonadotropin (β-hCG), serum
96%–98%
1.5%–3.5%
˂1%
β-Human chorionic gonadotropin (β-hCG), urine
Hydroxyproline, urine
Immature platelet fraction
˂1.0
20–50 μg/24 hr
5–15 μmol/L
Female, premenopausal nonpregnant: ˂1.0 U/L; female,
postmenopausal: ˂7.0 U/L; male: ˂1.4 U/L
˂2 mIU/24 hr
10–30 mg/sq meter of body surface/24 hr
1%–5% of platelet count
Immune complexes, serum
0–50 μg/dL
6
Immunoglobulins, serum
IgA
IgE
IgG
IgM
90–325 mg/dL
˂380 IU/mL
800–1500 mg/dL
45–150 mg/dL
Immunoglobulin free light chains, serum
Kappa
Lambda
Kappa-to-lambda ratio
3.3–19.4 mg/L
5.7–26.3 mg/L
0.26–1.65
Insulin, serum (fasting)
˂20 μU/mL
Insulin-like growth factor 1 (IGF-1)
(somatomedin-C), serum
Ages 16–24
Ages 25–39
Ages 40–54
Ages 55 and older
182–780 ng/mL
114–492 ng/mL
90–360 ng/mL
71–290 ng/mL
Iodine, urine
Random ("spot")
µg/L; varies
Iron, serum
Iron-binding capacity, serum (total)
Lactate dehydrogenase, serum
Lactate, arterial blood
50–150 μg/dL
250–310 μg/dL
80–225 U/L
˂1.3 mmol/L (˂1.3 mEq/L)
Lactate, serum or plasma
Lactate, venous blood
Lactic acid, serum
Lactose tolerance test, GI
Lead, blood
0.7–2.1 mmol/L
0.7–1.8 mEq/L; 6–16 mg/dL
6–19 mg/dL (0.7–2.1 mmol/L)
Increase in plasma glucose: >15 mg/dL
<5.0 μg/dL
Leukocyte count
Segmented neutrophils
Band forms
Lymphocytes
Monocytes
Basophils
Eosinophils
4000–11,000/μL
50%–70%
0%–5%
30%–45%
0%–6%
0%–1%
0%–3%
Lipase, serum
10–140 U/L
Lipoprotein(a), serum
Lithium, plasma
Therapeutic
Toxic level
Desirable: ˂30 mg/dL
Luteinizing hormone (LH), serum
Female, follicular/luteal
Female, mid-cycle peak
Female, postmenopausal
Male (adult)
Children, Tanner stages 1, 2, 3
Children, Tanner stages 4, 5
0.6–1.2 mEq/L
>2 mEq/L
1–12 mIU/mL (1–12 U/L)
9–80 mIU/mL (9–80 U/L)
>30 mIU/mL (>30 U/L)
2–9 mIU/mL (2–9 U/L)
˂9.0 mIU/mL (˂9.0 U/L)
1–15 mIU/mL (1–15 U/L)
7
Lymphocyte subsets
CD3
CD4
CD8
CD19
CD56
Magnesium, serum
Magnesium, urine
Mean corpuscular hemoglobin
Mean corpuscular hemoglobin concentration
Mean corpuscular volume
Mean platelet volume
Metanephrines, fractionated, plasma
Metanephrine
Normetanephrine
Metanephrines, fractionated, 24-hour urine
Metanephrine
Normetanephrine
900–3245/μL
530–1570/μL
430–1060/μL
208–590/μL
40–500/µL
1.6–2.6 mEq/L
14–290 mg/24 hr
28–32 pg
33–36 g/dL
80–98 fL
7–9 fL
˂0.5 nmol/L
˂0.9 nmol/L
˂400 µg/24 hr
˂900 µg/24 hr
Methylmalonic acid, serum
Myoglobin, serum
0.00–0.40 µmol/L
˂100 μg/L
Norepinephrine, plasma
Supine
Standing
70–750 pg/mL
200–1700 pg/mL
Norepinephrine, urine
0–100 μg/24 hr
Normetanephrine, fractionated, plasma
Normetanephrine, fractionated, 24-hour urine
N -telopeptide, urine
˂0.9 nmol/L
˂900 µg/24 hr
Female: 11–48 nmol BCE/mmol creatinine;
male: 7–68 nmol BCE/mmol creatinine
N -terminal-pro-B-type natriuretic peptide (NT-pro-BNP), If eGFR >60 mL/min/1.73 m2
serum or plasma
18 –49 years of age
Heart failure unlikely: ≤300 pg/mL
High probability of heart failure: ≥450 pg/mL
50–75 years of age
Heart failure unlikely: ≤300 pg/mL
High probability of heart failure: ≥900 pg/mL
Older than 75 years of age
Heart failure unlikely: ≤300 pg/mL
High probability of heart failure: ≥1800 pg/mL
2
If eGFR <60 mL/min/1.73 m
18 years of age or older
High probability of heart failure: ≥1200 pg/mL
Osmolality, serum
275–295 mOsm/kg H2O
Osmolality, urine
38–1400 mOsm/kg H2O
Osmotic fragility of erythrocytes
Increased if hemolysis occurs in over 0.5% NaCl;
decreased if hemolysis is incomplete in 0.3% NaCl
Osteocalcin, serum
Female: 7.2–27.9 ng/mL; male: 11.3–35.4 ng/mL
Oxalate, urine
˂40 mg/24 hr
Oxygen consumption
Oxygen saturation, arterial blood
225–275 mL/min
≥95%
Parathyroid hormone, serum
C -terminal
Intact
150–350 pg/mL
10–65 pg/mL
Intact (dialysis patients only)
Target: 130–585 pg/mL
8
Parathyroid hormone-related protein, serum
Partial thromboplastin time (activated)
pH, urine
˂1.5 pmol/L
25–35 seconds
4.5–8.0
Phenolsulfonphthalein, urine
Phenytoin, serum
At least 25% excreted by 15 minutes;
40% by 30 minutes;
60% by 120 minutes
Therapeutic: 10–20 μg/mL
Phosphatase (acid), serum
Total
Prostatic fraction
0.5–2.0 (Bodansky) units/mL
0.1–0.4 unit/mL
Phosphatase (alkaline), serum
Phospholipids, serum (total)
Phosphorus, serum
30–120 U/L
200–300 mg/dL
3.0–4.5 mg/dL
Phosphorus, urine
Platelet count
500–1200 mg/24 hr
150,000–450,000/μL
Platelet function analysis (PFA-100):
Collagen–epinephrine closure time
Collagen–ADP closure time
Platelet survival rate (51Cr)
Potassium, serum
60–143 seconds
58–123 seconds
10 days
3.5–5.0 mEq/L
Potassium, urine
Random ("spot")
24-hour measurement
mEq/L; varies
mEq/24 hr; varies with intake
Prealbumin, serum
Pregnanetriol, urine
Pressure (opening) [initial], CSF
Procalcitonin, serum
16–30 mg/dL
0.2–3.5 mg/24 hr
70–180 mm CSF (70–180 mm H2O); 7–18 cm H2O
≤0.10 ng/mL
Progesterone, serum
Female, follicular
Female, luteal
Male (adult)
0.02–0.9 ng/mL
2–30 ng/mL
0.12–0.3 ng/mL
Proinsulin, serum
Prolactin, serum
3–20 pmol/L
˂20 ng/mL
Prostate-specific antigen, serum
Protein C activity, plasma
Protein C antigen, plasma
Protein catabolic rate, urine
Protein S activity, plasma
Protein S antigen, plasma
Total
Free
Protein, urine
Random ("spot")
24-hour measurement
ng/mL; no specific normal or abnormal level
65%–150%
70%–140%
goal: 1.0–1.2 g/kg/24 hr
57%–131%
Proteins, CSF total
Proteins, serum
Total
Albumin
15–45 mg/dL
60%–140%
60%–130%
mg/dL; varies
˂100 mg/24 hr
5.5–9.0 g/dL
3.5–5.5 g/dL
9
Proteins, serum (continued)
Globulin
Alpha1
Alpha2
Beta
Gamma
2.0–3.5 g/dL
0.2–0.4 g/dL
0.5–0.9 g/dL
0.6–1.1 g/dL
0.7–1.7 g/dL
Protein-to-creatinine ratio, urine
Prothrombin time, plasma
Pyruvic acid, blood
Quinidine, serum
Red cell distribution width (RDW)
Red cell mass
˂0.2 mg/mg
11–13 seconds
0.08–0.16 mmol/L
Therapeutic: 2–5 μg/mL
9.0%–14.5%
Female: 22.7–27.9 mL/kg; male: 24.9–32.5 mL/kg
Renin activity (angiotensin-I radioimmunoassay)
Peripheral plasma
Normal diet
Supine
Upright
Low sodium diet
Supine
Upright
Diuretics + low sodium diet
Renal vein concentration
0.3–2.5 ng/mL/hr
0.2–3.6 ng/mL/hr
0.9–4.5 ng/mL/hr
4.1–9.1 ng/mL/hr
6.3–13.7 ng/mL/hr
Normal ratio (high:low): ˂1.5
Reptilase time
Reticulocyte count
10–12 seconds
0.5%–1.5% of red cells
Reticulocyte count, absolute
Rheumatoid factor (nephelometry)
Rheumatoid factor, latex test for
Ristocetin cofactor activity of plasma
Sodium, serum
25,000–100,000/µL
˂24 IU/mL
≤1:80
See von Willebrand factor activity (ristocetin cofactor
activity), plasma
33–44 seconds
Therapeutic: 20–30 mg/dL
Female, nonpregnant: 18–144 nmol/L;
male: 10–57 nmol/L
136–145 mEq/L
Sodium, urine
Random ("spot")
24-hour measurement
mEq/L; varies
mEq/24 hr; varies with intake
Specific gravity, urine
Sperm density
Sweat test for sodium and chloride
1.002–1.030
10–150 million/mL
˂60 mEq/L
T3 resin uptake
T-lymphocyte count, CD4
Tacrolimus, whole blood (trough)
Testosterone, serum
Testosterone, bioavailable, serum
25%–35%
530–1570/μL
Therapeutic: 5–15 ng/mL {For transplant patients:
10.0–15.0 ng/mL (0–3 months post transplantation);
5.0–10.0 ng/mL (more than 3 months post
transplantation)}
Female: 18–54 ng/dL; male: 291–1100 ng/dL
Female, age 18–69 yrs: 0.5–8.5 ng/dL
Testosterone, free, serum
Theophylline, serum
Thrombin time
Male: 70–300 pg/mL
Therapeutic: 8–20 μg/mL
17–23 seconds
Russell viper venom time, dilute
Salicylate, plasma
Sex hormone-binding globulin
10
Thyroid function studies
T3 resin uptake
Thyroglobulin, serum
123
Thyroidal iodine ( I) uptake
Thyroid-stimulating hormone (TSH), serum
Thyroid-stimulating immunoglobulin (TSI)
Thyroxine-binding globulin, serum
Thyroxine index, free (estimate)
Thyroxine (T4), serum
Total
Free
Triiodothyronine (T3), serum
Total
Reverse
Free
25%–35%
˂20 ng/mL
5%–30% of administered dose at 24 hours
0.5–4.0 μU/mL (0.5–4.0 mU/L)
˂130%
12–27 µg/mL
5–12
5–12 μg/dL
0.8–1.8 ng/dL
80–180 ng/dL
20–40 ng/dL
2.3–4.2 pg/mL
Tissue transglutaminase antibody, IgA
[by chemiluminescence method]
Tissue transglutaminase antibody, IgG
[by chemiluminescence method]
Tissue transglutaminase antibody, IgA
[by ELISA]
˂20 AU
Tissue transglutaminase antibody, IgG
[by ELISA]
Total proteins, CSF
Transaminase, serum glutamic oxaloacetic (SGOT)
Transaminase, serum glutamic pyruvic (SGPT)
Transferrin saturation
Transferrin, serum
˂6.0 U/mL
˂20 AU
˂4.0 U/mL
15–45 mg/dL
See Aminotransferase, serum aspartate (AST)
See Aminotransferase, serum alanine (ALT)
20%–50%
200–400 mg/dL
Triglycerides, serum (fasting)
Optimal
Normal
Borderline-high
High
Very high
˂100 mg/dL
˂150 mg/dL
150–199 mg/dL
200–499 mg/dL
>499 mg/dL
Troponin I, cardiac, serum
Troponin T, cardiac, serum
Troponin I, cardiac, high-sensitivity, plasma
Troponin T, cardiac, high-sensitivity, plasma
Tryptase, serum
≤0.04 ng/mL
≤0.01 ng/mL
Female: ≤15 ng/L; male: ≤20 ng/L
Female: ≤10 ng/L; male: ≤15 ng/L
˂11.5 ng/mL
Urea clearance, urine
Standard
Maximal
40–60 mL/min
60–100 mL/min
Urea nitrogen, blood
Urea nitrogen, urine
Uric acid, serum
Uric acid, urine
Uroporphyrin, urine
Vanillylmandelic acid, urine
8–20 mg/dL
12–20 g/24 hr
3.0–7.0 mg/dL
250–750 mg/24 hr
10–30 μg/24 hr
˂9 mg/24 hr
Venous oxygen content, mixed
14–16 mL/dL
11
Venous studies, mixed, blood
pH
PCO2
PO2
Bicarbonate
Oxygen saturation (SvO2)
7.32–7.41
42–53 mm Hg
35–42 mm Hg
24–28 mEq/L
65%–75%
Viscosity, serum
1.4–1.8 cp
Vitamin A, serum:
Adult
Pediatric, age 1–2 yr (retinol)
32.5–78.0 μg/dL
20–43 μg/dL
Vitamin B12, serum
200–800 pg/mL
Vitamin D metabolites, serum
1,25-Dihydroxyvitamin D
(1,25-dihydroxycholecalciferol)
25-Hydroxyvitamin D
(25-hydroxycholecalciferol)
Vitamin E, serum:
Adult
Pediatric, age 1–2 yr (alpha-tocopherol)
Volume, blood
Plasma
Red cell
von Willebrand factor activity (ristocetin cofactor
activity), plasma
von Willebrand factor antigen, plasma
Zinc, serum
15–60 pg/mL
30–60 ng/mL
5.5–17.0 mg/L
2.9–16.6 mg/L
Female: 43 mL/kg body weight;
male: 44 mL/kg body weight
Female: 20–30 mL/kg body weight;
male: 25–35 mL/kg body weight
50%–150%
50%–150%
75–140 μg/dL
Revised - July 2023
13